Columbia Science Review
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact

Finally, a light in the darkness: New genetic testing of tumors provides more accurate predictions than ever.

4/8/2013

0 Comments

 
Picture
By Alex Bernstein

Until quite recently, oncologists, despite all of the progress that has been made in the field, could at best make educated guesses when asked about survival chances by patients. When Cassandra Caton, an 18-year-old tragically diagnosed with a large melanoma growth inside her eye, asked, “Am I going to die, is my baby going to have a mommy in 5 years?” doctors were only able to make a prediction based on the shape and size of the tumor.

Now, however, Caton has a much better option. A new genetic test, pioneered by J. William Harbour of Washington University, could provide her with a remarkably accurate prognosis. Identifying which one of the two chief types of genetic patterns the patient’s melanoma falls into, this novel test is able to place the patient’s cancer into either Class 1 or Class 2. The former represents the milder tumor, which is essentially cured through surgery, while the latter is indicative of a more aggressive malignancy, which claims the lives of about 70 to 80% of patients within five years. Remarkably, the test is even detailed enough to predict where future potential cancer growth might appear during metastasis (the spread of cancer), accurately predicting that the liver is the organ to be watched.

So far only available for ocular melanoma, the test represents great progress in the oncology community. Dr. Michael Birrer, specialist in ovarian cancer at the Massachusetts General Hospital, is more than enthusiastic about the procedure, calling it “unbelievably impressive,” going as far as saying, “I would die to have something like that in ovarian cancer.”

Similar prediction procedures are already in the works for other cancers, such as those of the blood and bones.

However, as is usually the case with new science, ethical issues are raised. People often have trouble finding out if they have the genetic makeup for certain incurable disorders such as early Alzheimer’s or Huntington’s disease. The same can be said for such a cancer test, which will either essentially assure patients of their survival, or signify almost certain death. Some doctors even opt to not offer the test, suggesting that there aren’t many benefits it can provide in terms of treatment. A melanoma researcher at Massachusetts General, Dr. Keith Flaherty explains that although the test is able to separate people into two prognostic groups, “There is no treatment yet that will alter the natural history of the disease.”

Yet despite such concerns, most doctors do believe in the test, and as Dr. Harbour notes, the overwhelming majority of patients ask for it. When dealing with something like cancer, people want to be as informed as possible. Harbour explains that he gives patients “as much information as [he thinks] they can handle.”

Dr. Harbor continues to express his support for the test as he suggests that a Class 2 identification can provide the doctor with the opportunity to better manage the melanoma by knowing what to expect and what tests to run. Regardless, the procedure signifies great progress and hints at just how important genetic testing will be to the future successes in this field.
​
As for Ms. Caton, despite the large size of her tumor, the cancer turned out to be Class 1, a very positive diagnosis that would not be possible without the test.
0 Comments



Leave a Reply.

    Categories

    All
    Artificial Intelligence
    Halloween 2022

    Archives

    November 2022
    October 2022
    June 2022
    January 2022
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    November 2019
    October 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    April 2018
    March 2018
    February 2018
    November 2017
    October 2017
    May 2017
    April 2017
    April 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    May 2014
    April 2014
    March 2014
    February 2014
    December 2013
    November 2013
    October 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    April 2011
    March 2011
    February 2011
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010
    January 2010
    December 2009
    November 2009
    July 2009
    May 2009

Columbia Science Review
© COPYRIGHT 2022. ALL RIGHTS RESERVED.
Photos used under Creative Commons from driver Photographer, BrevisPhotography, digitalbob8, Rennett Stowe, Kristine Paulus
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact